Abstract
Background: Clinical trials have shown impressive survival in patients who received 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) chemotherapy after resection of pancreatic ductal adenocarcinoma (PDAC). However, the true efficacy in a real-world population remains unknown. The aim of this study was to assess the impact of different adjuvant chemotherapy regimens on overall survival (OS) in an unselected cohort of patients who underwent PDAC resection.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: HPB : the official journal of the International Hepato Pancreato Biliary Association
Paper Title
Journal
Date
